Cloverfields Capital Group Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lifestance Health
LFST
|
+$33.6M |
| 2 |
Canadian Pacific Kansas City
CP
|
+$4.28M |
| 3 |
SLB Ltd
SLB
|
+$2.96M |
| 4 |
Teck Resources
TECK
|
+$2.94M |
| 5 |
Masco
MAS
|
+$2.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NLSN
Nielsen Holdings plc
NLSN
|
+$4.24M |
| 2 |
Hilton Worldwide
HLT
|
+$3.36M |
| 3 |
Charter Communications
CHTR
|
+$3.1M |
| 4 |
Snap
SNAP
|
+$2.83M |
| 5 |
JD.com
JD
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.72% |
| 2 | Technology | 6.71% |
| 3 | Consumer Staples | 5.5% |
| 4 | Financials | 4.96% |
| 5 | Communication Services | 4.04% |
Similar funds
Cloverfields Capital Group's Q2 2022 Portfolio in Review
As of Q2 2022, Cloverfields Capital Group held 78 positions worth $328M, up 2.4% from $320M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Cloverfields Capital Group deployed $38M of net new capital in Q2 2022, opening 14 new positions and adding to 29 existing holdings. Its largest new stake was Lifestance Health: 4,385,841 shares worth $24.4M.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 61% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was JD.com, an estimated $2.27M trimmed.
- Cloverfields Capital Group's largest Q2 2022 buy was Lifestance Health: 4,385,841 shares worth $24.4M.
- Cloverfields Capital Group added most to SLB Ltd in Q2 2022, an estimated $2.96M increase.
- Cloverfields Capital Group's biggest Q2 2022 reduction was JD.com, cutting an estimated $2.27M.
- Cloverfields Capital Group fully exited Nielsen Holdings plc in Q2 2022, selling an estimated $4.24M.
- Cloverfields Capital Group's ten largest holdings make up 74% of its $328M portfolio in Q2 2022.
- Cloverfields Capital Group opened 14 new positions and closed 8 in Q2 2022.
- Cloverfields Capital Group's portfolio value rose 2.4% quarter-over-quarter to $328M.
Based on Cloverfields Capital Group's 13F filing for Q2 2022, filed 12 Aug 2022.